Dose-response, net clinical benefit and optimal dose ranges of stimulants in children and adolescents with ADHD: a network meta-analysis
European Child & Adolescent Psychiatry · 2026
DOI: 10.1007/s00787-026-03025-3 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift European Child & Adolescent Psychiatry, 2026. Verfasst von Yu Chang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Chung Shan Medical University Hospital, Taichung City, Taiwan. Hauptthemen laut MEDLINE: Central Nervous System Stimulants, Methylphenidate, Attention Deficit Disorder with Hyperactivity, Amphetamines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chung Shan Medical University.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Stimulant treatment with methylphenidate (MPH) and amphetamines (AMP) is first-line for children and adolescents with attention-deficit/hyperactivity disorder (ADHD), but quantitative guidance on comparative efficacy and dose selection within licensed dose ranges remains limited. This study aimed to compare dose-response relationships for MPH and AMP and identify dose ranges that balance symptom improvement and adverse event-related discontinuation across benefit-risk preferences. CENTRAL, PubMed, and Embase were searched from inception to August 12, 2025 for double-blind randomized trials of fixed-dose MPH or AMP in patients aged 5-18 years with ADHD. A Bayesian random-effects dose-response network meta-analysis estimated symptom change and discontinuation due to adverse events. Benefits and harms were integrated using net clinical benefit (NCB) across a range of risk-preference values to reflect real-world variation in benefit-harm trade-offs. Forty-eight trials (4,964 participants) were included. For both drugs, efficacy increased with dose and then plateaued (approximately 45 mg/day for MPH and 25 mg/day for AMP), while adverse event-related discontinuation rose steadily with higher doses. Across plausible preferences, AMP generally achieved higher maximal NCB than MPH. Under neutral preferences, population-level NCB was highest at approximately 18-46 mg/day for MPH (peak 30-39 mg/day) and 12-26 mg/day for AMP (peak 18-20 mg/day). By combining dose-response modeling with a net clinical benefit translation, we identified preference-sensitive, comparative dose ranges for MPH and AMP to support more transparent stimulant selection and dose titration in routine care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Chung Shan Medical University Hospital, Taichung City, Taiwan.
- School of Medicine, Chung Shan Medical University, No. 110, Jianguo N. Rd., Sec. 1, Taichung City, 40201, Taiwan.
- Post Baccalaureate Medicine, National Chung Hsing University, Taichung City, Taiwan. purpplewhale@yahoo.com.tw.
- Department of Health Business Administration, Hungkuang University, Taichung City, Taiwan. purpplewhale@yahoo.com.tw.
- Department of Psychiatry, Changhua Christian Children's Hospital, Changhua, Taiwan. purpplewhale@yahoo.com.tw.
- Department of Psychiatry, Changhua Christian Hospital, No.135, Nanhsiao Street, 500, Changhua, Taiwan. purpplewhale@yahoo.com.tw.
Förderung
- Chung Shan Medical University
Zitieren
APA
Chang, Y., Ju, P. C., Hsieh, M. H., Liu, Y. C., & Chang, C. C. (2026). Dose-response, net clinical benefit and optimal dose ranges of stimulants in children and adolescents with ADHD: a network meta-analysis. European Child & Adolescent Psychiatry. https://doi.org/10.1007/s00787-026-03025-3
Vancouver
Chang Y, Ju PC, Hsieh MH, Liu YC, Chang CC. Dose-response, net clinical benefit and optimal dose ranges of stimulants in children and adolescents with ADHD: a network meta-analysis. European Child & Adolescent Psychiatry. 2026. doi:10.1007/s00787-026-03025-3
BibTeX
@article{Chang2026,
author = {Chang, Yu and Ju, Po-Chung and Hsieh, Ming-Hong and Liu, Yi-Chun and Chang, Cheng-Chen},
title = {Dose-response, net clinical benefit and optimal dose ranges of stimulants in children and adolescents with ADHD: a network meta-analysis},
journal = {European Child & Adolescent Psychiatry},
year = {2026},
doi = {10.1007/s00787-026-03025-3}
}
EUVIMED